Výsledky vyhledávání

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Autor: M B Manning, D A Streja, C Keller, C H Chung, P L Beckett, A Özdemir, Y M Cho, I Colin, L J Aronne, Erik Christiansen, Markus Laimer, L Van Gaal, S N Lederman, T M O'Connor, L J Klaff, S Aronoff, S H Baik, A V Murray, Signe O R Wallenstein, N A Godbole, H O Høivik, Dilek Gogas Yavuz, A Golay, G T'Sjoen, B Delgado, I N El Ebrashy, E S Kang, C Wium, Bruce W. Bode, Ramazan Sari, B A Palchick, J Geohas, P R Nicol, M Winnie, N Aladağ, E W Braun, C Vercammen, S A Shelbaya, K Sivalingam, S Gorban de Lapertosa, E Riffer, F G Eliaschewitz, J B Buse, B Schultes, C H Sorli, K-W Lee, Mark Warren, T Pieber, S Stäuble, R Prager, A Mertens, A A Arif, D C Eagerton, A Scheen, I J Kim, J A Seo, S Ong, E Ataoglu, John B. Buse, D Berker, A White, F Helland, J C LaRocque, Young Min Cho, Christin L. Hertz, E M Palace, L H S Canani, M P Finneran, S H A Khalil, H L Gulseth, D Weiss, J Condit, E Fließer-Görzer, L Rista, S Akın, M H M F El Hefnawy, N H Kim, C Issa, S Bilz, H Bays, S Fischli, V Preumont, J Pereles-Ortiz, B Bode, E J Morawski, Aytekin Oguz, J Cooper, Tamer Tetiker, Ann Mertens, G Rudofsky, Thomas R. Pieber, W R Litchfield, J L Gross, D L Weinstein

Publikováno v: The lancet. Diabetesendocrinology. 7(7)

BACKGROUND: Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes. We aimed to compare the efficacy and safety of flexible dose adjustments of oral semaglut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e132376f3cbf48c52376523aef27e59f
https://pubmed.ncbi.nlm.nih.gov/31320282

Zobrazit plný text záznamu

Initiating insulin therapy in elderly patients with Type 2 diabetes

Autor: Jessie L. Fahrbach, Sherry Martin, H. Jiang, Bruce H. R. Wolffenbuttel, R. Bhushan, L. J. Klaff

Publikováno v: Diabetic Medicine, 26(11), 1147-1155. Wiley

AimsTo compare starter insulins in the elderly subgroup of the DURABLE trial 24-week initiation phase.MethodsIn a post-hoc analysis of the >= 65 years subgroup enrolled in the DURABLE trial, we compared the safety and efficacy of lispro mix 25 (LM25:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0964b9fda7e3d7ee146feb5ddc576fa9
https://doi.org/10.1111/j.1464-5491.2009.02824.x

Zobrazit plný text záznamu

Recombinant Glucagon-like Peptide-1 (7-36 amide) Lowers Fasting Serum Glucose in a Broad Spectrum of Patients with Type 2 Diabetes

Autor: H. D. Kay, R. Schneider, R. E. Harley, R. Brazg, L. J. Klaff, David A. D'Alessio, M. R. Ehlers, A. L. Mathisen

Publikováno v: Hormone and Metabolic Research. 35:611-616

Aims: To evaluate the safety and efficacy of various doses of recombinant glucagon-like peptide-1 (7-36) amide (rGLP-1) administered subcutaneously (s. c.) via bolus injection or continuous infusion to lower fasting serum glucose (FSG) levels in subj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d0dcd45d291ab9205227397f238a745
https://doi.org/10.1055/s-2003-43509

Zobrazit plný text záznamu

Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDDM patients. 5-yr follow-up of the Seattle Family Study

Autor: D. K. McCulloch, L. J. Klaff, S. E. Kahn, S. L. Schoenfeld, C. J. Greenbaum, R. S. Mauseth, E. A. Benson, G. T. Nepom, L. Shewey, J. P. Palmer

Publikováno v: Diabetes. 39:549-556

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::baa869f2fc2d1b9947ce408a2cd3e914
https://doi.org/10.2337/diabetes.39.5.549

Zobrazit plný text záznamu

The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes

Autor: Stephanie A. Amiel, Sherwyn Schwartz, Simon Heller, David G. Maggs, Ian A. Macdonald, Orville G. Kolterman, Christian Weyer, L J Klaff, James A. Ruggles

Publikováno v: Diabetes, obesitymetabolism. 7(5)

Background: Pramlintide, a human amylin analogue, is a potential new adjunctive therapy to insulin for patients with type 1 diabetes and insulin-using patients with type 2 diabetes. Early clinical trials have shown a transient increased risk of hypog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::598f34eeb8a1d42282540c8ea92e70a8
https://pubmed.ncbi.nlm.nih.gov/16050943

Zobrazit plný text záznamu

Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM

Autor: L J Klaff, C. Corder, Alan Gottlieb, Sherwyn Schwartz, B. Levy, J. Peterson, Orville G. Kolterman

Publikováno v: Diabetologia. 39(4)

Individuals with insulin-dependent diabetes mellitus (IDDM or type 1 diabetes) are deficient in both insulin and amylin, peptides secreted by the beta cell. We have investigated the effects of amylin replacement therapy employing the human amylin ana

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8cd1d4b25fc137b5a287a3e7606947c
https://pubmed.ncbi.nlm.nih.gov/8778001

Zobrazit plný text záznamu

Role of pancreatic somatostatin in determining glucagon response to arginine and morphine

Autor: G. J. Taborsky, L. J. Klaff

Publikováno v: American Journal of Physiology-Endocrinology and Metabolism. 252:E751-E755

It has been proposed that pancreatic somatostatin (SS) tonically inhibits pancreatic glucagon secretion. In keeping with this hypothesis, we have previously shown that infusion of a nonimmunoreactive analogue of SS, [D-Ala5,D-Trp8]somatostatin (SSa),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c37fd81851807368c9db04a799aee7a4
https://doi.org/10.1152/ajpendo.1987.252.6.e751

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání